Metabolic / Insulin Resistance
1. Root Cause Overview
Insulin resistance is a state in which target tissues (muscle, liver, adipose) fail to respond normally to insulin signalling, leading to compensatory hyperinsulinaemia, progressive beta-cell exhaustion, and ultimately type 2 diabetes. It is the central metabolic defect in metabolic syndrome and is associated with cardiovascular disease, PCOS, NAFLD, cognitive decline, and cancer. Root causes include excess caloric intake (particularly refined carbohydrates and fructose), physical inactivity, sleep deprivation, chronic stress, gut dysbiosis, environmental toxins, and genetic predisposition.
2. Common Signs & Symptoms
- Central obesity (waist circumference >88 cm women, >102 cm men)
- Fatigue after meals (postprandial energy crash)
- Carbohydrate and sugar cravings
- Acanthosis nigricans (dark skin patches in skin folds)
- Elevated fasting glucose (>5.6 mmol/L) or HbA1c (>5.7%)
- Elevated fasting insulin (>10 μIU/mL) or HOMA-IR >2.0
- Elevated triglycerides (>1.7 mmol/L)
- Low HDL (<1.0 mmol/L women, <1.3 mmol/L men)
- Hypertension (>130/85 mmHg)
- PCOS symptoms in women (irregular cycles, hirsutism)
3. Labs to Consider
Fasting glucose, fasting insulin, HbA1c, HOMA-IR calculation, lipid panel, liver enzymes (NAFLD), uric acid, CBC/CMP.
Choose the lab option based on what you want to assess within this root cause.
Blood Spot Cardiometabolic
ZRT Laboratory
4. Clinical Priorities
Assess the major contributors to insulin resistance in the individual case, which may include excess refined carbohydrate intake, low muscle mass, visceral adiposity, sleep disruption, chronic stress, inflammation, medication effects, nutrient insufficiency, or PCOS. Use diet, movement, body-composition goals, sleep, and stress support as core tools, while correcting relevant deficits such as magnesium, chromium, or vitamin D. Metformin or GLP-1 agonists may be appropriate in clinical diabetes and should be coordinated with the prescribing physician.
Where to Start: Top 2 Supplements
The most clinically validated natural insulin sensitiser. Meta-analyses show efficacy comparable to metformin for reducing HbA1c, fasting glucose, and fasting insulin. Activates AMPK (the cellular energy sensor), improves gut microbiome, and reduces lipids simultaneously. First-line nutraceutical for insulin resistance.
Magnesium deficiency is present in up to 80% of patients with insulin resistance and type 2 diabetes. Magnesium is required for insulin receptor function and glucose transport. RCT evidence confirms improvement in fasting glucose and insulin sensitivity. Addresses a root cause, not just a symptom.
5. Diet Strategy
Adopt a low-glycaemic, whole-food dietary pattern: eliminate refined sugars, white flour, and ultra-processed foods. Prioritise non-starchy vegetables, legumes, whole grains, lean proteins, and healthy fats (olive oil, avocado, nuts). Consider time-restricted eating (16:8 intermittent fasting) — shown to significantly improve insulin sensitivity. Reduce fructose (particularly from sugar-sweetened beverages and processed foods). Apple cider vinegar (1–2 tbsp before meals) reduces postprandial glucose spikes.
6. Lifestyle Strategy
Resistance training is the most potent intervention for improving insulin sensitivity — increases GLUT4 transporter expression in muscle. Aim for 3–4 sessions/week. Aerobic exercise (150 min/week) provides additional benefit. Post-meal walking (10–15 min) significantly reduces postprandial glucose. Prioritise 7–9 hours of sleep — even one night of sleep deprivation causes significant insulin resistance. Manage chronic stress — cortisol directly impairs insulin signalling.
7. Supplement Strategy
Full supplement list below. See Section 4 (Clinical Priorities) for the recommended Top 2 starting supplements. Add additional supplements based on lab results and clinical response at 4–6 week reassessment.
| Supplement | Dosage | Indication | Evidence | Key Results | Example |
|---|---|---|---|---|---|
| Berberine [1] GI upset (nausea, constipation, diarrhoea); CYP3A4 interactions; contraindicated in pregnancy | 500 mg TID (1,500 mg/day total) with meals | Insulin sensitisation (AMPK activation); glucose and lipid lowering; gut microbiome modulation | Meta-analysis of RCTs | Comparable to metformin for reducing HbA1c, fasting glucose, and fasting insulin; improved lipid profile | Thorne Berberine-500 |
| Chromium Picolinate [2] Generally well tolerated at recommended doses; high doses may cause kidney damage | 400–1,000 mcg/day | Insulin receptor sensitisation; glucose tolerance improvement; carbohydrate craving reduction | Meta-analysis of RCTs | Significant reduction in fasting glucose and HbA1c in type 2 diabetes; improved insulin sensitivity | Thorne Chromium Picolinate |
| Alpha-Lipoic Acid (ALA) [3] Hypoglycaemia risk — monitor blood glucose; GI upset; caution with thyroid medications | 600–1,200 mg/day | Insulin sensitisation; GLUT4 translocation; antioxidant protection of beta cells | RCT and meta-analysis | Significantly reduced fasting glucose, insulin resistance (HOMA-IR), and oxidative stress markers in T2DM | Klaire Labs Alpha Lipoic Acid |
| Magnesium Glycinate [4] Loose stools at high doses; caution in renal impairment | 300–400 mg elemental magnesium/day | Insulin receptor function; glucose metabolism; >300 enzymatic reactions | Meta-analysis of RCTs | Significant improvement in fasting glucose and insulin sensitivity in hypomagnesaemic individuals with T2DM | Pure Encapsulations Magnesium Glycinate |
| Cinnamon Extract (Cinnamomum cassia or verum) [5] Coumarin content in cassia — use Ceylon cinnamon or aqueous extract for long-term use; anticoagulant interaction | 1–6 g/day (or 120–360 mg aqueous extract) | Insulin mimetic activity; postprandial glucose reduction; lipid improvement | Meta-analysis of RCTs | Significant reduction in fasting blood glucose, total cholesterol, LDL, and triglycerides | Integrative Therapeutics Cinnamon Force |
| Inositol (Myo-Inositol + D-Chiro-Inositol, 40:1 ratio) [6] Generally well tolerated; mild GI upset at high doses; may lower blood sugar — monitor in diabetics | 2,000–4,000 mg myo-inositol + 50–100 mg D-chiro-inositol/day | Insulin signal transduction; PCOS-associated insulin resistance; ovarian function | Systematic review and meta-analysis | Significantly improved insulin resistance, fasting glucose, and hormonal parameters in PCOS | Theralogix Ovasitol |
8. Safety Notes
Berberine has significant drug interactions (CYP3A4 substrates) and is contraindicated in pregnancy. ALA and chromium can cause hypoglycaemia — monitor blood glucose closely in patients on diabetes medications. Do not use inositol as a replacement for medical management of T2DM. Refer for confirmed T2DM, HbA1c >8%, or cardiovascular complications. Coordinate with prescribing physician when adding supplements to patients on metformin or insulin.
9. Citations & References
- [1]BerberineYin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717.View source
- [2]Chromium PicolinateBalk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007;30(8):2154–2163.View source
- [3]Alpha-Lipoic Acid (ALA)Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69.View source
- [4]Magnesium GlycinateRodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003;26(4):1147–1152.View source
- [5]Cinnamon Extract (Cinnamomum cassia or verum)Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013;11(5):452–459.View source
- [6]Inositol (Myo-Inositol + D-Chiro-Inositol, 40:1 ratio)Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509–515.View source
Ask AI About This Protocol
Related Mini-Training
12:18Functional Gastroenterology Quick Start
9:47SIBO: Causes, Testing & Treatment
10:15Anti-Inflammatory Nutrition